Wed, Sep 17, 2014, 11:03 AM EDT - U.S. Markets close in 4 hrs 57 mins


% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

plain_ole_pain 2 posts  |  Last Activity: Jul 27, 2014 5:03 PM Member since: Mar 8, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • plain_ole_pain plain_ole_pain Jul 27, 2014 5:03 PM Flag

    You are exactly right on all fronts Mark. Big pharma has a love hate relationship with company like Inovio. On one hand Inovio can be great for new products to partner with however, on the other hand Inovio could end up becoming bigger than the company they partnered with. Proof of concept doesn't just stop with what's in the pipeline but with what ever target they want to set their sites on. Not good for big pharma when that could have major impact on present compounds and ancillary treatments to such things as cancer and infectious disease. If something is cured there is no need for long term drugs to control things such as post pain or nausea and such. So yes big pharma likes but doesn't like Inovio's science the proverbial catch 22 to say the least.

    Ask yourself how many LEEP procedures are performed every year? What happens if you cut that rate done by 50%? What happens to docs/facility costs that perform the procedure and the meds to control infection, pain, nausea, and other possible follow on sequel such as miscarriages, fertility issues and other cancers. This starts to add up very quickly, cures can really cost someone a lot of money. Guess who?

  • plain_ole_pain plain_ole_pain Jun 27, 2014 8:28 AM Flag

    I would have sometimes over half page of blocked posts from bashers on each page. Now I can’t find one till 16 hours ago. That seems like a long lunch break to me especially when working from a boiler room.

    Sentiment: Strong Buy

10.60+0.10(+0.95%)11:02 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.